Institute of Toxicology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
PLoS One. 2011;6(10):e26413. doi: 10.1371/journal.pone.0026413. Epub 2011 Oct 19.
Radiotherapy (RT) plays a key role in cancer treatment. Although the benefit of ionizing radiation (IR) is well established, some findings raise the possibility that irradiation of the primary tumor not only triggers a killing response but also increases the metastatic potential of surviving tumor cells. Here we addressed the question of whether irradiation of normal cells outside of the primary tumor augments metastasis by stimulating the extravasation of circulating tumor cells. We show that IR exposure of human endothelial cells (EC), tumor cells (TC) or both increases TC-EC adhesion in vitro. IR-stimulated TC-EC adhesion was blocked by the HMG-CoA reductase inhibitor lovastatin. Glycyrrhizic acid from liquorice root, which acts as a Sialyl-Lewis X mimetic drug, and the Rac1 inhibitor NSC23766 also reduced TC-EC adhesion. To examine the in vivo relevance of these findings, tumorigenic cells were injected into the tail vein of immunodeficient mice followed by total body irradiation (TBI). The data obtained show that TBI dramatically enhances tumor cell extravasation and lung metastasis. This pro-metastatic radiation effect was blocked by pre-treating mice with lovastatin, glycyrrhizic acid or NSC23766. TBI of mice prior to tumor cell transplantation also stimulated metastasis, which was again blocked by lovastatin. The data point to a pro-metastatic trans-effect of RT, which likely rests on the endothelial radiation response promoting the extravasation of circulating tumor cells. Administration of the widely used lipid-lowering drug lovastatin prior to irradiation counteracts this process, likely by suppressing Rac1-regulated E-selectin expression following irradiation. The data support the concern that radiation exposure might increase the extravasation of circulating tumor cells and recommend co-administration of lipid-lowering drugs to avoid this adverse effect of ionizing radiation.
放射治疗(RT)在癌症治疗中起着关键作用。虽然电离辐射(IR)的益处已得到充分证实,但一些研究结果表明,照射原发性肿瘤不仅会引发杀伤反应,还会增加存活肿瘤细胞的转移潜力。在这里,我们研究了照射原发性肿瘤以外的正常细胞是否通过刺激循环肿瘤细胞的渗出来增加转移的问题。我们发现,体外照射人内皮细胞(EC)、肿瘤细胞(TC)或两者均能增加 TC-EC 黏附。HMG-CoA 还原酶抑制剂洛伐他汀可阻断 IR 刺激的 TC-EC 黏附。来自甘草根的甘草酸,作为唾液酸化-Lewis X 模拟药物,以及 Rac1 抑制剂 NSC23766 也降低了 TC-EC 黏附。为了研究这些发现的体内相关性,将致瘤性细胞注入免疫缺陷小鼠的尾静脉,然后进行全身照射(TBI)。获得的数据表明,TBI 显著增强了肿瘤细胞的渗出和肺转移。预先用洛伐他汀、甘草酸或 NSC23766 预处理小鼠可阻断这种促转移的辐射效应。在肿瘤细胞移植前对小鼠进行 TBI 也会刺激转移,而洛伐他汀再次阻断了这种作用。这些数据表明 RT 具有促转移的跨效应,这可能依赖于促进循环肿瘤细胞渗出的内皮辐射反应。在照射前给予广泛使用的降脂药洛伐他汀可抑制这种作用,可能是通过抑制照射后 Rac1 调节的 E-选择素表达。这些数据支持这样一种担忧,即辐射暴露可能会增加循环肿瘤细胞的渗出,并建议联合使用降脂药物以避免电离辐射的这种不良影响。